Vaxcyte, Inc. (NASDAQ:PCVX) Given Average Rating of “Moderate Buy” by Brokerages

Vaxcyte, Inc. (NASDAQ:PCVX) has received a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $93.8333.

Several research analysts recently commented on the company. Leerink Partners set a $77.00 target price on Vaxcyte and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Guggenheim restated a “buy” rating and issued a $116.00 price objective on shares of Vaxcyte in a research note on Monday, February 2nd. Needham & Company LLC lifted their target price on shares of Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. BTIG Research reissued a “buy” rating and issued a $85.00 target price on shares of Vaxcyte in a research note on Monday, November 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, January 9th.

Vaxcyte Trading Down 1.0%

Shares of PCVX stock opened at $55.57 on Tuesday. Vaxcyte has a 12 month low of $27.66 and a 12 month high of $87.42. The company has a market capitalization of $7.27 billion, a P/E ratio of -11.48 and a beta of 1.33. The stock has a 50 day moving average of $48.24 and a two-hundred day moving average of $41.68.

Insider Activity at Vaxcyte

In other Vaxcyte news, SVP Elvia Cowan sold 11,623 shares of the stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $47.92, for a total transaction of $556,974.16. Following the completion of the transaction, the senior vice president directly owned 14,534 shares in the company, valued at $696,469.28. This represents a 44.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Harpreet S. Dhaliwal sold 9,743 shares of the business’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $46.69, for a total transaction of $454,900.67. Following the completion of the sale, the insider owned 23,928 shares in the company, valued at $1,117,198.32. This represents a 28.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Vaxcyte

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PCVX. EverSource Wealth Advisors LLC grew its stake in Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after buying an additional 184 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of Vaxcyte by 148.9% in the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after acquiring an additional 731 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new position in shares of Vaxcyte in the 3rd quarter worth approximately $45,000. CIBC Private Wealth Group LLC grew its position in Vaxcyte by 22,500.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock worth $49,000 after acquiring an additional 1,350 shares during the last quarter. Finally, CWM LLC increased its holdings in Vaxcyte by 197.3% during the 2nd quarter. CWM LLC now owns 1,680 shares of the company’s stock valued at $55,000 after purchasing an additional 1,115 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.